ALB and neoplasm: A breakthrough strategy conjugates ARV-771 to ECMal linkers that spontaneously bind serum albumin, achieving tumor-selective PROTAC release via esterase cleavage—resulting in 16.3-fold greater tumor accumulation and 5.3-fold enhanced therapeutic index versus free PROTAC while eliminating systemic toxicity (Figure 6A) [89].